Of note, elevated levels of PDL1 are observed in NSCLC patients [283,284,285,286], and PD1/PDL1 checkpoint inhibitors have become routinely part of the clinical approach for management of NSCLC [287,288,289,290]. Here, PDCD1 is linked to non-small cell lung carcinoma.